{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:40:18Z","timestamp":1791837618958,"version":"4.3.4"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Infect Dis"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose of review<\/jats:title>\n                <jats:p>The goal of this review was to provide an update on the prevention and treatment options for invasive candidiasis (IC) in the neonatal intensive care unit (NICU) and pediatric intensive care unit (PICU).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent findings<\/jats:title>\n                <jats:p>Studies have further validated the use of fluconazole for IC prophylaxis among high-risk patients in the NICU. It remains unclear if prophylaxis leads to resistance development and the ideal dosage regimen is still not clear. Recent studies have been published comparing caspofungin and micafungin to amphotericin B and illustrated similar efficacy outcomes in the NICU. Micafungin now has approval from the United States Food and Drug Administration (FDA) for use in infants\u2009&lt;\u20094\u00a0months of age. Prophylactic strategies in the PICU could include zinc and vitamin D. Anidulafungin has recent non-comparative data supporting use in pediatric patients older than 1\u00a0month of age and also has a recent FDA approval for use in children 1\u00a0month of age and older.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Fluconazole prophylaxis remains a reasonable strategy in select NICU patients, although further analyses of resistance and the optimal dosage regimen are needed. Echinocandins are potential therapeutic options for non-meningitis or urinary tract infections in both the neonatal and pediatric population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40506-022-00258-z","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T16:04:30Z","timestamp":1652717070000},"page":"15-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Updates in the Pharmacologic Prophylaxis and Treatment of Invasive Candidiasis in the Pediatric and Neonatal Intensive Care Units"],"prefix":"10.1007","volume":"14","author":[{"given":"James Hunter","family":"Fly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seerat","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Bobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Stultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"issue":"1","key":"258_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/ice.2017.236","volume":"39","author":"JG Lake","year":"2018","unstructured":"Lake JG, Weiner LM, Milstone AM, Saiman L, Magill SS, See I. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011\u20132014. Infect Control Hosp Epidemiol. 2018;39(1):1\u201311. https:\/\/doi.org\/10.1017\/ice.2017.236.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"9","key":"258_CR2","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/PCC.0000000000000254","volume":"15","author":"A Ruth","year":"2014","unstructured":"Ruth A, McCracken CE, Fortenberry JD, Hall M, Simon HK, Hebbar KB. Pediatric severe sepsis: current trends and outcomes from the Pediatric Health Information Systems database. Pediatr Crit Care Med. 2014;15(9):828\u201338. https:\/\/doi.org\/10.1097\/PCC.0000000000000254.","journal-title":"Pediatr Crit Care Med"},{"issue":"suppl_1","key":"258_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/jpids\/pix046","volume":"6","author":"ZD Pana","year":"2017","unstructured":"Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T. Epidemiology of invasive fungal disease in children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S3\u201311. https:\/\/doi.org\/10.1093\/jpids\/pix046.","journal-title":"J Pediatric Infect Dis Soc."},{"issue":"4","key":"258_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"258_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/cid\/cir800","volume":"54","author":"JL Wynn","year":"2012","unstructured":"Wynn JL, Tan S, Gantz MG, Das A, Goldberg RN, Adams-Chapman I, et al. Outcomes following candiduria in extremely low birth weight infants. Clin Infect Dis. 2012;54(3):331\u20139. https:\/\/doi.org\/10.1093\/cid\/cir800.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"258_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1542\/peds.2013-0671","volume":"133","author":"S Aliaga","year":"2014","unstructured":"Aliaga S, Clark RH, Laughon M, Walsh TJ, Hope WW, Benjamin DK, et al. Changes in the incidence of candidiasis in neonatal intensive care units. Pediatrics. 2014;133(2):236\u201342. https:\/\/doi.org\/10.1542\/peds.2013-0671.","journal-title":"Pediatrics"},{"issue":"3\u20134","key":"258_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.riam.2020.09.005","volume":"37","author":"AI Piqueras","year":"2020","unstructured":"Piqueras AI, Rubio T, Lopez-Medina EM, Gimeno A, Modesto V, Canton E, et al. Recent changes in candidemia trends in a tertiary hospital (2011\u20132018). Rev Iberoam Micol. 2020;37(3\u20134):87\u201393. https:\/\/doi.org\/10.1016\/j.riam.2020.09.005.","journal-title":"Rev Iberoam Micol"},{"issue":"8","key":"258_CR8","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/INF.0000000000000274","volume":"33","author":"I Jordan","year":"2014","unstructured":"Jordan I, Balaguer M, Lopez-Castilla JD, Belda S, Shuffelman C, Garcia-Teresa MA, et al. Per-species risk factors and predictors of invasive Candida infections in patients admitted to pediatric intensive care units: development of ERICAP scoring systems. Pediatr Infect Dis J. 2014;33(8):e187\u201393. https:\/\/doi.org\/10.1097\/INF.0000000000000274.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"258_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1542\/peds.2004-2292","volume":"117","author":"DK Benjamin Jr","year":"2006","unstructured":"Benjamin DK Jr, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;117(1):84\u201392. https:\/\/doi.org\/10.1542\/peds.2004-2292.","journal-title":"Pediatrics"},{"issue":"Suppl 7","key":"258_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/1469-0691.12040","volume":"18","author":"WW Hope","year":"2012","unstructured":"Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18(Suppl 7):38\u201352. https:\/\/doi.org\/10.1111\/1469-0691.12040.","journal-title":"Clin Microbiol Infect"},{"key":"258_CR11","unstructured":"Amphotericin B for injection [package insert]. Big Flats, NY: X-Gen Pharmaceuticals, Inc; 2010."},{"issue":"1","key":"258_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12879-018-3410-4","volume":"18","author":"JS Stultz","year":"2018","unstructured":"Stultz JS, Kohinke R, Pakyz AL. Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America. BMC Infect Dis. 2018;18(1):501. https:\/\/doi.org\/10.1186\/s12879-018-3410-4.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"258_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1097\/INF.0000000000002463","volume":"38","author":"L Ferreras-Antolin","year":"2019","unstructured":"Ferreras-Antolin L, Irwin A, Atra A, Dermirjian A, Drysdale SB, Emonts M, et al. Neonatal antifungal consumption is dominated by prophylactic use; outcomes from the pediatric antifungal stewardship: optimizing antifungal prescription study. Pediatr Infect Dis J. 2019;38(12):1219\u201323. https:\/\/doi.org\/10.1097\/INF.0000000000002463.","journal-title":"Pediatr Infect Dis J"},{"key":"258_CR14","doi-asserted-by":"publisher","first-page":"CD003850","DOI":"10.1002\/14651858.CD003850.pub4","volume":"4","author":"N Austin","year":"2013","unstructured":"Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2013;4:CD003850. https:\/\/doi.org\/10.1002\/14651858.CD003850.pub4.","journal-title":"Cochrane Database Syst Rev."},{"key":"258_CR15","doi-asserted-by":"publisher","first-page":"CD003850","DOI":"10.1002\/14651858.CD003850.pub5","volume":"10","author":"J Cleminson","year":"2015","unstructured":"Cleminson J, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2015;10:CD003850. https:\/\/doi.org\/10.1002\/14651858.CD003850.pub5.","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"258_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.jp.7211914","volume":"28","author":"JH Weitkamp","year":"2008","unstructured":"Weitkamp JH, Ozdas A, LaFleur B, Potts AL. Fluconazole prophylaxis for prevention of invasive fungal infections in targeted highest risk preterm infants limits drug exposure. J Perinatol. 2008;28(6):405\u201311. https:\/\/doi.org\/10.1038\/sj.jp.7211914.","journal-title":"J Perinatol"},{"key":"258_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12887-016-0605-y","volume":"16","author":"J Lee","year":"2016","unstructured":"Lee J, Kim HS, Shin SH, Choi CW, Kim EK, Choi EH, et al. Efficacy and safety of fluconazole prophylaxis in extremely low birth weight infants: multicenter pre-post cohort study. BMC Pediatr. 2016;16:67. https:\/\/doi.org\/10.1186\/s12887-016-0605-y.","journal-title":"BMC Pediatr"},{"issue":"4","key":"258_CR18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3345\/cep.2019.01431","volume":"64","author":"M Robati Anaraki","year":"2021","unstructured":"Robati Anaraki M, Nouri-Vaskeh M, Abdoli OS. Fluconazole prophylaxis against invasive candidiasis in very low and extremely low birth weight preterm neonates: a systematic review and meta-analysis. Clin Exp Pediatr. 2021;64(4):172\u20139. https:\/\/doi.org\/10.3345\/cep.2019.01431.","journal-title":"Clin Exp Pediatr"},{"key":"258_CR19","doi-asserted-by":"publisher","unstructured":"Leonart LP, Tonin FS, Ferreira VL, Tavares da Silva Penteado S, de Araujo Motta F, Pontarolo R. Fluconazole doses used for prophylaxis of invasive fungal infection in neonatal intensive care units: a network meta-analysis. J Pediatr. 2017;185:129\u201335 e6. https:\/\/doi.org\/10.1016\/j.jpeds.2017.02.039.","DOI":"10.1016\/j.jpeds.2017.02.039"},{"issue":"9","key":"258_CR20","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1128\/AAC.00963-16","volume":"60","author":"JD Momper","year":"2016","unstructured":"Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, et al. Population pharmacokinetics of fluconazole in premature infants with birth weights less than 750 grams. Antimicrob Agents Chemother. 2016;60(9):5539\u201345. https:\/\/doi.org\/10.1128\/AAC.00963-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"258_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/INF.0b013e31819f1f50","volume":"28","author":"KC Wade","year":"2009","unstructured":"Wade KC, Benjamin DK Jr, Kaufman DA, Ward RM, Smith PB, Jayaraman B, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28(8):717\u201323. https:\/\/doi.org\/10.1097\/INF.0b013e31819f1f50.","journal-title":"Pediatr Infect Dis J"},{"key":"258_CR22","doi-asserted-by":"publisher","unstructured":"Autmizguine J, Smith BP, Prather K, Bendel C, Natarajan G, Bidegain M, et al. Effect of fluconazole prophylaxis on Candida fluconazole susceptibility in premature infants. J Antimicrob Chemother. 2018;73:3482-87. https:\/\/doi.org\/10.1093\/jac\/dky353. This is an important recent study that provides information regarding the impact of fluconazole prophylaixs on Candida fluconazole susceptibility.","DOI":"10.1093\/jac\/dky353"},{"issue":"9","key":"258_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/INF.0000000000001913","volume":"37","author":"J Autmizguine","year":"2018","unstructured":"Autmizguine J, Tan S, Cohen-Wolkowiez M, Cotten CM, Wiederhold N, Goldberg RN, et al. Antifungal susceptibility and clinical outcome in neonatal candidiasis. Pediatr Infect Dis J. 2018;37(9):923\u20139. https:\/\/doi.org\/10.1097\/INF.0000000000001913.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"258_CR24","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3109\/14767058.2015.1013933","volume":"29","author":"H Kirpal","year":"2016","unstructured":"Kirpal H, Gathwala G, Chaudhary U, Sharma D. Prophylactic fluconazole in very low birth weight infants admitted to neonatal intensive care unit: randomized controlled trial. J Matern Fetal Neonatal Med. 2016;29(4):624\u20138. https:\/\/doi.org\/10.3109\/14767058.2015.1013933.","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"1","key":"258_CR25","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1097\/ANC.0000000000000640","volume":"20","author":"IT Chen","year":"2020","unstructured":"Chen IT, Chen CC, Huang HC, Kuo KC. Malassezia furfur emergence and candidemia trends in a neonatal intensive care unit during 10 years: the experience of fluconazole prophylaxis in a single hospital. Adv Neonatal Care. 2020;20(1):E3\u20138. https:\/\/doi.org\/10.1097\/ANC.0000000000000640.","journal-title":"Adv Neonatal Care"},{"key":"258_CR26","doi-asserted-by":"publisher","unstructured":"Driessen M, Ellis JB, Cooper PA, Wainer S, Muwazi F, Hahn D, et al. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J. 1996;15(12):1107\u201312. doi: https:\/\/doi.org\/10.1097\/00006454-199612000-00011.","DOI":"10.1097\/00006454-199612000-00011"},{"issue":"4","key":"258_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jac\/dkg419","volume":"52","author":"N Linder","year":"2003","unstructured":"Linder N, Klinger G, Shalit I, Levy I, Ashkenazi S, Haski G, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother. 2003;52(4):663\u20137. https:\/\/doi.org\/10.1093\/jac\/dkg419.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"258_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/INF.0b013e3182467a72","volume":"31","author":"SB Ascher","year":"2012","unstructured":"Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31(5):439\u201343. https:\/\/doi.org\/10.1097\/INF.0b013e3182467a72.","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"258_CR29","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","volume":"27","author":"F Queiroz-Telles","year":"2008","unstructured":"Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J. 2008;27(9):820\u20136. https:\/\/doi.org\/10.1097\/INF.0b013e31817275e6.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"258_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/tropej\/fmr025","volume":"58","author":"WA Mohamed","year":"2012","unstructured":"Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. J Trop Pediatr. 2012;58(1):25\u201330. https:\/\/doi.org\/10.1093\/tropej\/fmr025.","journal-title":"J Trop Pediatr."},{"key":"258_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2147\/IDR.S118892","volume":"10","author":"EL Berkow","year":"2017","unstructured":"Berkow EL, Lockhart SR. Fluconazole resistance in Candida species: a current perspective. Infect Drug Resist. 2017;10:237\u201345. https:\/\/doi.org\/10.2147\/IDR.S118892.","journal-title":"Infect Drug Resist"},{"issue":"suppl_3","key":"258_CR32","doi-asserted-by":"publisher","first-page":"S445","DOI":"10.1093\/infdis\/jix131","volume":"216","author":"MC Arendrup","year":"2017","unstructured":"Arendrup MC, Patterson TF. Multidrug-resistant candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(suppl_3):S445\u201351. https:\/\/doi.org\/10.1093\/infdis\/jix131.","journal-title":"J Infect Dis."},{"key":"258_CR33","unstructured":"Mycamine [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2020."},{"key":"258_CR34","unstructured":"Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2019."},{"key":"258_CR35","unstructured":"Eraxis [package insert]. New York, NY: Pfizer, Inc; 2020."},{"key":"258_CR36","doi-asserted-by":"publisher","unstructured":"Benjamin DK, Jr., Kaufman DA, Hope WW, Smith PB, Arrieta A, Manzoni P, et al. A phase 3 study of micafungin versus amphotericin B deoxycholate in infants with invasive candidiasis. Pediatr Infect Dis J. 2018;37(10):992\u20138. doi: https:\/\/doi.org\/10.1097\/INF.0000000000001996. This is an important recent comparative study, albeit small, potentially supporting micafungin use in neonates and infants for IC.","DOI":"10.1097\/INF.0000000000001996"},{"key":"258_CR37","doi-asserted-by":"publisher","unstructured":"Kim J, Nakwa FL, Araujo Motta F, Liu H, Dorr MB, Anderson LJ, et al. A randomized, double-blind trial investigating the efficacy of caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and infants younger than 3 months of age. J Antimicrob Chemother. 2020;75(1):215\u201320. doi: https:\/\/doi.org\/10.1093\/jac\/dkz398. This is an important recent comparative study, albeit small, potentially supporting caspofungin use in neonates and infants for IC.","DOI":"10.1093\/jac\/dkz398"},{"issue":"7","key":"258_CR38","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/INF.0000000000002353","volume":"38","author":"G Leverger","year":"2019","unstructured":"Leverger G, Timsit JF, Milpied N, Gachot B. Use of micafungin for the prevention and treatment of invasive fungal infections in everyday pediatric care in France: results of the MYRIADE study. Pediatr Infect Dis J. 2019;38(7):716\u201321. https:\/\/doi.org\/10.1097\/INF.0000000000002353.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"258_CR39","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1086\/655698","volume":"51","author":"TE Zaoutis","year":"2010","unstructured":"Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis. 2010;51(5):e38-45. https:\/\/doi.org\/10.1086\/655698.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"258_CR40","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1097\/INF.0000000000002186","volume":"37","author":"ZD Pana","year":"2018","unstructured":"Pana ZD, Kotzadamis D, Roilides E. Invasive candidiasis in pediatric intensive care unit: more challenges. Pediatr Infect Dis J. 2018;37(12):1309\u201311. https:\/\/doi.org\/10.1097\/INF.0000000000002186.","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"258_CR41","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1097\/INF.0000000000002394","volume":"38","author":"E Mantadakis","year":"2019","unstructured":"Mantadakis E, Tragiannidis A. Invasive fungal infections in the pediatric intensive care unit. Pediatr Infect Dis J. 2019;38(9):e216\u20138. https:\/\/doi.org\/10.1097\/INF.0000000000002394.","journal-title":"Pediatr Infect Dis J"},{"issue":"9872","key":"258_CR42","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0140-6736(12)61687-0","volume":"381","author":"AM Milstone","year":"2013","unstructured":"Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381(9872):1099\u2013106. https:\/\/doi.org\/10.1016\/S0140-6736(12)61687-0.","journal-title":"Lancet"},{"key":"258_CR43","doi-asserted-by":"publisher","unstructured":"Xie J, Zhu L, Zhu T, Jian Y, Ding Y, Zhou M, et al. Zinc supplementation reduces Candida infections in pediatric intensive care unit: a randomized placebo-controlled clinical trial. J Clin Biochem Nutr. 2019;64(2):170-3. doi: https:\/\/doi.org\/10.3164\/jcbn.18-74. This study offers some evidence for a non-antifungal based prophylaxis approach in the PICU.","DOI":"10.3164\/jcbn.18-74"},{"issue":"4","key":"258_CR44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/jhn.12634","volume":"32","author":"J Xie","year":"2019","unstructured":"Xie J, Zhu L, Zhu T, Jian Y, Ding Y, Zhou M, et al. Vitamin D-supplemented yogurt drink reduces Candida infections in a paediatric intensive care unit: a randomised, placebo-controlled clinical trial. J Hum Nutr Diet. 2019;32(4):512\u20137. https:\/\/doi.org\/10.1111\/jhn.12634.","journal-title":"J Hum Nutr Diet"},{"issue":"6","key":"258_CR45","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ijantimicag.2019.02.019","volume":"53","author":"YH Chen","year":"2019","unstructured":"Chen YH, Cheng IL, Lai CC, Tang HJ. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: a meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2019;53(6):789\u201394. https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.02.019.","journal-title":"Int J Antimicrob Agents."},{"issue":"1","key":"258_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/INF.0000000000002032","volume":"38","author":"M Tsekoura","year":"2019","unstructured":"Tsekoura M, Ioannidou M, Pana ZD, Haidich AB, Antachopoulos C, Iosifidis E, et al. Efficacy and safety of echinocandins for the treatment of invasive candidiasis in children: a meta-analysis. Pediatr Infect Dis J. 2019;38(1):42\u20139. https:\/\/doi.org\/10.1097\/INF.0000000000002032.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"258_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/INF.0000000000002237","volume":"38","author":"E Roilides","year":"2019","unstructured":"Roilides E, Carlesse F, Leister-Tebbe H, Conte U, Yan JL, Liu P, et al. A prospective, open-label study to assess the safety, tolerability and efficacy of anidulafungin in the treatment of invasive candidiasis in children 2 to <18 years of age. Pediatr Infect Dis J. 2019;38(3):275\u20139. https:\/\/doi.org\/10.1097\/INF.0000000000002237.","journal-title":"Pediatr Infect Dis J"},{"key":"258_CR48","doi-asserted-by":"publisher","unstructured":"Roilides E, Carlesse F, Tawadrous M, Leister-Tebbe H, Conte U, Raber S, et al. Safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to < 2 years of age with invasive candidiasis, including candidemia. Pediatr Infect Dis J. 2020;39(4):305-9. doi: https:\/\/doi.org\/10.1097\/INF.0000000000002568. This is an important study that led to FDA approval of anidulaungin for use in younger pediatric patients.","DOI":"10.1097\/INF.0000000000002568"},{"issue":"11","key":"258_CR49","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","volume":"46","author":"C Logan","year":"2020","unstructured":"Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med. 2020;46(11):2001\u201314. https:\/\/doi.org\/10.1007\/s00134-020-06240-x.","journal-title":"Intensive Care Med"},{"key":"258_CR50","doi-asserted-by":"crossref","unstructured":"Bradley JS, Nelson JD, Barnett E, et al. Nelson\u2019s pediatric antimicrobial therapy. 22nd ed. American Academy of Pediatrics; 2019.","DOI":"10.1542\/9781610023535"},{"issue":"11","key":"258_CR51","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1128\/AAC.33.11.1989","volume":"33","author":"JM Benson","year":"1989","unstructured":"Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother. 1989;33(11):1989\u201393. https:\/\/doi.org\/10.1128\/AAC.33.11.1989.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"258_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/s0022-3476(88)80653-x","volume":"113","author":"G Koren","year":"1988","unstructured":"Koren G, Lau A, Klein J, Golas C, Bologa-Campeanu M, Soldin S, et al. Pharmacokinetics and adverse effects of amphotericin B in infants and children. J Pediatr. 1988;113(3):559\u201363. https:\/\/doi.org\/10.1016\/s0022-3476(88)80653-x.","journal-title":"J Pediatr"},{"issue":"1","key":"258_CR53","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1086\/315643","volume":"182","author":"AH Groll","year":"2000","unstructured":"Groll AH, Giri N, Petraitis V, Petraitiene R, Candelario M, Bacher JS, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274\u201382. https:\/\/doi.org\/10.1086\/315643.","journal-title":"J Infect Dis"},{"issue":"4","key":"258_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NR Stone","year":"2016","unstructured":"Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome((R))): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485\u2013500. https:\/\/doi.org\/10.1007\/s40265-016-0538-7.","journal-title":"Drugs"},{"issue":"12","key":"258_CR55","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","volume":"11","author":"AC Leenders","year":"1997","unstructured":"Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11(12):1463\u201371. https:\/\/doi.org\/10.1097\/00002030-199712000-00010.","journal-title":"AIDS"},{"issue":"5","key":"258_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/INF.0b013e318202cbb3","volume":"30","author":"L Piper","year":"2011","unstructured":"Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011;30(5):375\u20138. https:\/\/doi.org\/10.1097\/INF.0b013e318202cbb3.","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"258_CR57","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1128\/AAC.00569-08","volume":"52","author":"KC Wade","year":"2008","unstructured":"Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043\u20139. https:\/\/doi.org\/10.1128\/AAC.00569-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"258_CR58","unstructured":"Diflucan [package insert]. New York, NY: Pfizer, Inc; 2020."},{"issue":"4","key":"258_CR59","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1097\/MPH.0000000000001071","volume":"40","author":"A Strommen","year":"2018","unstructured":"Strommen A, Hurst AL, Curtis D, Abzug MJ. Use of intravenous posaconazole in hematopoietic stem cell transplant patients. J Pediatr Hematol Oncol. 2018;40(4):e203\u20136. https:\/\/doi.org\/10.1097\/MPH.0000000000001071.","journal-title":"J Pediatr Hematol Oncol"},{"key":"258_CR60","doi-asserted-by":"publisher","unstructured":"Ashley ED. Antifungal drugs: special problems treating central nervous system infections. J Fungi (Basel). 2019;5(4). https:\/\/doi.org\/10.3390\/jof5040097.","DOI":"10.3390\/jof5040097"},{"issue":"1","key":"258_CR61","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1128\/CMR.00046-13","volume":"27","author":"T Felton","year":"2014","unstructured":"Felton T, Troke PF, Hope WW. Tissue penetration of antifungal agents. Clin Microbiol Rev. 2014;27(1):68\u201388. https:\/\/doi.org\/10.1128\/CMR.00046-13.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"258_CR62","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1128\/AAC.05761-11","volume":"56","author":"LE Friberg","year":"2012","unstructured":"Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother. 2012;56(6):3032\u201342. https:\/\/doi.org\/10.1128\/AAC.05761-11.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"258_CR63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1046\/j.1365-2125.2003.01992.x","volume":"56","author":"L Purkins","year":"2003","unstructured":"Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol. 2003;56(Suppl 1):2\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01992.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"258_CR64","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/clpt.2011.26","volume":"89","author":"M Cohen-Wolkowiez","year":"2011","unstructured":"Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, Cheifetz IM, Moran C, Liu P, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther. 2011;89(5):702\u20137. https:\/\/doi.org\/10.1038\/clpt.2011.26.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"258_CR65","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","volume":"50","author":"DK Benjamin Jr","year":"2006","unstructured":"Benjamin DK Jr, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother. 2006;50(2):632\u20138. https:\/\/doi.org\/10.1128\/AAC.50.2.632-638.2006.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"258_CR66","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/bcp.13628","volume":"84","author":"S Leroux","year":"2018","unstructured":"Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Barin-Le Guellec C, Aurich B, et al. Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial. Br J Clin Pharmacol. 2018;84(9):1989\u201399. https:\/\/doi.org\/10.1111\/bcp.13628.","journal-title":"Br J Clin Pharmacol"},{"key":"258_CR67","doi-asserted-by":"publisher","unstructured":"Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Bruggemann RJ, Koster RA, et al. Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother. 2017;61(12). doi: https:\/\/doi.org\/10.1128\/AAC.01398-17.","DOI":"10.1128\/AAC.01398-17"},{"key":"258_CR68","doi-asserted-by":"publisher","unstructured":"Yanni SB, Smith PB, Benjamin DK, Jr., Augustijns PF, Thakker DR, Annaert PP. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm Drug Dispos. 2011;32(4):222\u201332. doi: https:\/\/doi.org\/10.1002\/bdd.752.","DOI":"10.1002\/bdd.752"}],"container-title":["Current Treatment Options in Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40506-022-00258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40506-022-00258-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40506-022-00258-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T02:09:28Z","timestamp":1653271768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40506-022-00258-z"}},"subtitle":["Updates in the Pharmacologic Prophylaxis"],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["258"],"URL":"https:\/\/doi.org\/10.1007\/s40506-022-00258-z","relation":{},"ISSN":["1534-6250"],"issn-type":[{"value":"1534-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"16 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors reports grants from the Pediatric Pharmacy Association Neonatal Pharmacy Resident Small Research Grant, all outside the submitted work; Dr. Stultz, Dr. Bobo, and Dr. Fly report grants from the Board of Pharmacy Specialties that is outside of the submitted work. Dr. Stultz also reports personal speaker fees from the Pediatric Pharmacy Association, grants from the National Institutes of Allergy and Infectious Diseases, and the American College of Clinical Pharmacy, all outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}